Thomas Boren

Title: Thomas Boren: Innovator in Blood Group Antigen Research

Introduction

Thomas Boren is a notable inventor based in Umea, Sweden. He has made significant contributions to the field of immunology, particularly in the development of novel blood group antigen binding proteins. With a total of 3 patents, his work has implications for diagnosing and treating gastrointestinal diseases.

Latest Patents

Boren's latest patents include a novel blood group antigen binding (BAB) adhesin protein that has been isolated and purified. This protein specifically binds to fucosylated blood group antigens. The patent discloses the protein sequence of the adhesin, along with the DNA sequences for two genes, babA and babB, which produce highly similar proteins. This adhesin and/or DNA is useful for diagnosis and therapy directed against induced infections, such as gastritis and acid peptic disease, facilitating active vaccination. Additionally, he has developed a new immunoglobulin composition that exhibits specific activity to a Lewis antigen binding adhesin. This offers a more efficient method for the treatment and prevention of gastrointestinal diseases, including passive vaccination against Helicobacter pylori.

Career Highlights

Throughout his career, Thomas Boren has worked with various companies, contributing his expertise to advance research in his field. His innovative work has led to significant advancements in the understanding of blood group antigens and their applications in medicine.

Collaborations

Boren has collaborated with notable colleagues, including Anna Arnqvist and Staffan Normark. These partnerships have further enriched his research and contributed to the success of his inventions.

Conclusion

Thomas Boren's contributions to the field of immunology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the diagnosis and treatment of gastrointestinal diseases.